Semaglutide.
1 proveedor · US$15–15
Agonista del receptor de GLP-1, aprobado por la FDA y la EMA como Ozempic, Wegovy y Rybelsus. La semaglutida de viales de investigación es distinta y no aprobada, no fabricada ni revisada como esos medicamentos, ni apta para uso humano.
El compuesto. Origen, investigación y realidad regulatoria.
Semaglutide is a synthetic GLP-1 receptor agonist developed by Novo Nordisk: a human GLP-1 analogue with amino-acid substitutions and a fatty-diacid side chain that binds albumin and extends the half-life to about one week. The FDA approved it as Ozempic for type 2 diabetes on 5 December 2017, as the oral tablet Rybelsus on 20 September 2019 and as the weight-management injection Wegovy on 4 June 2021; the medicines are also authorised by the EMA.
The SUSTAIN trial programme characterised its glucose-lowering action through GLP-1 receptor agonism in adults with type 2 diabetes, and SUSTAIN-6 (Marso et al., 2016) examined cardiovascular outcomes. The STEP programme (Wilding et al., 2021) studied its effect on body weight through appetite- and satiety-regulating GLP-1 pathways in adults with obesity or overweight, and SELECT (Lincoff et al., 2023) examined cardiovascular outcomes in obesity without diabetes; the PIONEER programme evaluated the oral formulation.
As Ozempic, Wegovy and Rybelsus, semaglutide is a prescription-only medicine manufactured and reviewed under FDA and EMA oversight. Research-use-only semaglutide vials sold outside that supply chain are not those products, have not been reviewed for safety, effectiveness or quality, and carry no human-use instructions. The FDA has warned of counterfeit Ozempic in the US supply chain, of fraudulently compounded semaglutide including unapproved salt forms, and has warned companies that illegally sold unapproved semaglutide falsely labelled ‘for research purposes’.
Cada proveedor. Mismo compuesto, ordenado ascendente.
Contexto de investigación. Trabajo reciente revisado por pares.
Lo que más se pregunta.
Is semaglutide legal to buy?
Ozempic, Wegovy and Rybelsus are prescription-only medicines. Research-use-only semaglutide vials are sold for laboratory research, not human use; RUO labelling does not make personal use or import legal everywhere.
How does research-vial semaglutide differ from Ozempic or Wegovy?
The approved pens are manufactured and reviewed under FDA/EMA oversight with device-controlled delivery. Research vials come from a different, unreviewed supply chain with no verified purity, sterility or delivery controls.
What should a CoA show for semaglutide?
HPLC purity, LC-MS mass confirmation matching C187H291N45O59 (MW ~4114), a lot number, an independent third-party lab name and a test date. The FDA has warned of salt forms (semaglutide sodium or acetate) misrepresented as the base peptide.